July 18th 2025
The phase 2 Co-PSMA trial enrolled 50 patients with biochemical recurrence of prostate cancer.
GU Tumor Board: Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies
September 27, 2025
Register Now!
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
View More
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Study suggests AI can improve detection of extraprostatic extension on MRI
December 11th 2023Utilizing a deep learning-based AI algorithm to differentiate between diagnostic and non-diagnostic quality of prostate MRI facilitated a 10% higher specificity rate for diagnosing extraprostatic extension on multiparametric MRI, according to research presented at the 2023 RSNA Annual Meeting.
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
Study of imaging agent for PSMA-negative prostate cancer hits enrollment goal
November 7th 2023“Preclinical and clinical findings thus far indicate that SAR-Bombesin holds significant potential for improving the diagnosis and treatment of prostate cancer,” said lead principal investigator Andrei Iagaru, MD.